NCT05367778View on ClinicalTrials.gov

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

June 3, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

HS-10370

HS-10370 will be administered orally once daily in a continuous regimen

Trial Locations (1)

430000

RECRUITING

Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY